1. CDK4/6 Inhibitors

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction Metastatic Breast Cancer

4. Mechanisms of Endocrine Resistance

5. MONALEESA-2 Ribociclib Plus Letrozole vs Letrozole Plus Placebo

6. PFS in MONALEESA-2

7. MONALEESA-2 Updated Results

8. MONALEESA-2: Grade 3/4 AEs

9. Ongoing Ribociclib Clinical Trials

10. Abemaciclib

11. MONARCH 2: Abemaciclib in Progressive Disease

12. PALOMA-1: First-Line Therapy With Palbociclib

13. PALOMA-2: First-Line Therapy With Palbociclib

14. PALOMA-3: Palbociclib in Progressive Disease

15. Management of ER+ Metastatic Breast Cancer in 2017

16. Neutropenia Management and Monitoring

17. QT Prolongation Management and Monitoring

18. Liver Toxicity Management and Monitoring

19. Conclusions

20. Abbreviations

21. Abbreviations (cont)